Tracee Fultz is the Life Sciences Transfer Pricing Leader for Ernst & Young LLP. Tracee advises clients in the areas of pharmaceutical, biotech and medical device intercompany pricing.
Tracee also serves as a broader health care thought leader for the global Ernst & Young organization’s pharmaceutical center, including as an advisor to the top 30 accounts in life sciences globally.
Tracee is a member of Ernst & Young’s LLP steering committee on health care reform for tax and healthcare policy issues. She is often featured on alerts related to health care reform and thought leadership.
Tracee previously worked as a manager of transfer pricing in Amgen’s tax department. She has distinguished herself as a practical life sciences tax resource who applies industry knowledge and health economics to help companies solve problems.
Tracee received an MPA in Health Care Management and Policy from New York University focused on health care economics. She is a mathematician and health services researcher.
She is the co-author of “What Color is Your Swan? Why Biotech Companies Need to Plan (and Expect) the Unexpected,” published in the Journal of Biolaw and Business. Her current research focuses on health economics and pay for performance and includes “The Lifecycle of Oncology Drugs and the Orphan Drug Act,” as well as “The Effect of HLA Matching Factor on Racial Disparities of Kidney Transplant Recipients.”
She is the recipient of Healthcare Woman’s Business Association’s “Rising Star Award” for 2008.